



Ventripoint Expands Advisory Board with addition of Ultrasound AI Executive

For Immediate Release

Toronto, Ontario – April 30, 2025 – Ventripoint Diagnostics Ltd. ("**Ventripoint**" or the "**Company**"), (TSXV:VPT; OTC:VPTDF) has increased the depth of its commercial experience with the addition of Stuart Gall to the company's Business Advisory Board to provide advice and guidance on the commercialization of Ventripoint's AI-powered, heart-scanning technology by hospitals and clinics around the world.

With its proprietary VMS+™ platform, Ventripoint is revolutionizing cardiac diagnostics by delivering a powerful AI-driven solution that enhances echocardiography and serves as an affordable and more accessible alternative to traditional MRI scans. Following recent regulatory milestones, Ventripoint is now primed to expand its presence in key markets and drive widespread adoption

A seasoned health technology executive, Stuart is Chief Executive Officer of Intelligent Ultrasound (AIM: MED), a company that develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity simulators for the ultrasound training market. Based in the UK and US, Intelligent Ultrasound has a portfolio of market leading products used in approximately 500 medical institutions around the world. Previously, Stuart was a joint founder and executive director of Fusion IP plc, an AIM listed IP commercialisation company, that was acquired for £103 million. Stuart has over 25 years' experience in both small company start-ups and public companies and previously worked at British Airways plc, The Promotions Partnership Limited, Anvil Limited and Toad plc (now 21st Century Technology plc).

"Stuart has demonstrated the ability to repeatedly build successful technology ventures" said Ventripoint's CEO Hugh MacNaught. "With VMS+™ 4.0 being cleared for sale in multiple markets Stuart's insights and experience and will be extremely helpful in advancing Ventripoint toward commercial success."

Added Gall: "Ventripoint's VMS+™ offers an AI enhancement to echocardiography that provides a fast, inexpensive and accessible alternative to MRIs. This product enables active cardiology practices to provide more timely management of the needs of patients with complex and challenging conditions."

For further information, please contact:

Hugh MacNaught

hmacnaught@ventripoint.com

(604) 671-4201



Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

Forward Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Company. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to several factors and risks. Factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis that is available on the Company's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether because of new information, future events or otherwise, unless so required by applicable securities laws.